Autologous Doping with Cryopreserved Red Blood Cells - Effects on Physical Performance and Detection by Multivariate Statistics

PLoS One. 2016 Jun 10;11(6):e0156157. doi: 10.1371/journal.pone.0156157. eCollection 2016.

Abstract

The discovery of erythropoietin (EPO) simplified blood doping in sports, but improved detection methods, for EPO has forced cheating athletes to return to blood transfusion. Autologous blood transfusion with cryopreserved red blood cells (RBCs) is the method of choice, because no valid method exists to accurately detect such event. In endurance sports, it can be estimated that elite athletes improve performance by up to 3% with blood doping, regardless of method. Valid detection methods for autologous blood doping is important to maintain credibility of athletic performances. Recreational male (N = 27) and female (N = 11) athletes served as Transfusion (N = 28) and Control (N = 10) subjects in two different transfusion settings. Hematological variables and physical performance were measured before donation of 450 or 900 mL whole blood, and until four weeks after re-infusion of the cryopreserved RBC fraction. Blood was analyzed for transferrin, iron, Hb, EVF, MCV, MCHC, reticulocytes, leucocytes and EPO. Repeated measures multivariate analysis of variance (MANOVA) and pattern recognition using Principal Component Analysis (PCA) and Orthogonal Projections of Latent Structures (OPLS) discriminant analysis (DA) investigated differences between Control and Transfusion groups over time. Significant increase in performance (15 ± 8%) and VO2max (17 ± 10%) (mean ± SD) could be measured 48 h after RBC re-infusion, and remained increased for up to four weeks in some subjects. In total, 533 blood samples were included in the study (Clean = 220, Transfused = 313). In response to blood transfusion, the largest change in hematological variables occurred 48 h after blood donation, when Control and Transfused groups could be separated with OPLS-DA (R2 = 0.76/Q2 = 0.59). RBC re-infusion resulted in the best model (R2 = 0.40/Q2 = 0.10) at the first sampling point (48 h), predicting one false positive and one false negative. Over all, a 25% and 86% false positives ratio was achieved in two separate trials. In conclusions, autologous re-infusion of RBCs increased VO2max and performance as hypothesized, but hematological profiling by multivariate statistics could not reach the WADA stipulated false positive ratio of <0.001% at any time point investigated. A majority of samples remained within limits of normal individual variation at all times.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Athletes
  • Athletic Performance / physiology*
  • Blood Donors
  • Blood Transfusion, Autologous*
  • Cryopreservation*
  • Doping in Sports / methods*
  • Erythrocyte Count
  • Erythrocytes*
  • Female
  • Humans
  • Male
  • Substance Abuse Detection / methods*

Grants and funding

This work was funded by World Anti Doping Agency (WADA) R07A1CM and 08C06CM (www.wada-ama.org), Sweden's innovation agency (VINNOVA) 2009-00462 (www.vinnova.se), Centrum för Idrottsforskning (CIF) 2008 88/08 (http://centrumforidrottsforskning.se), and Umeå Biotech Incubator (www.ubi.se). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.